Case Control Study
Copyright ©The Author(s) 2021.
World J Diabetes. Feb 15, 2021; 12(2): 138-148
Published online Feb 15, 2021. doi: 10.4239/wjd.v12.i2.138
Table 1 Baseline characteristics, disease information and laboratory data of the healthy controls, without diabetic retinopathy, non-proliferative diabetic retinopathy and proliferative diabetic retinopathy groups
Healthy controls (n = 118)DM
P value

NDR (n = 57)
NPDR (n = 64)
PDR (n = 61)
Baseline characteristics
Gender (male, %)56 (48.70)27 (47.37)26 (40.63)29 (47.54)0.947
Age (yr)59.84 ± 9.6058.21 ± 7.7560.89 ± 9.9365.72 ± 8.36< 0.001
BMI (kg/m2)26.11 ± 3.18 27.39 ± 3.71 26.86 ± 2.7625.93 ± 3.890.047
SBP (mmHg)123.53 ± 14.47 126.82 ± 17.62 131.66 ± 10.63 136.34 ± 11.87< 0.001
DBP (mmHg)73.97 ± 12.08 73.54 ± 12.69 81.14 ± 15.42 77.52 ± 13.090.0019
MAP (mmHg)90.49 ± 9.41 91.30 ± 10.86 97.98 ± 10.78 97.13 ± 10.04< 0.001
Disease information
Diabetes duration (yr)-5.72 ± 2.64 10.92 ± 6.0112.52 ± 4.96< 0.001
Fasting blood glucose (mg/dL)84.73 ± 23.85 133.81 ± 24.98143.28 ± 36.25167.86 ± 40.42< 0.001
HbA1C (%)5.87 ± 1.327.85 ± 1.698.61 ± 2.119.27 ± 1.80< 0.001
Use of oral hypoglycemic agents-38 (66.67)50 (78.13)44 (72.13)0.369
Use of insulin-15 (26.31)24 (37.50)21 (34.43)0.408
Hypertension (n, %)52 (44.07)25 (43.86)38 (59.38)41 (67.21)0.009
Smoking (n, %)37 (31.36)14 (24.56)18 (28.13)19 (31.15)0.801
Drinking (n, %)41 (34.75)20 (30.09)19 (29.69)24 (39.34)0.730
Laboratory data
Triglycerides (mmol/L)4.70 ± 1.50 4.79 ± 1.28 4.55 ± 1.28 4.88 ± 1.200.567
Total cholesterol (mmol/L)4.57 ± 1.54 5.01 ± 1.64 4.25 ± 1.77 4.77 ± 1.790.077
LDL cholesterol (mmol/L)3.12 ± 1.122.96 ± 1.20 2.98 ± 1.09 2.87 ± 0.940.504
HDL cholesterol (mmol/L)1.18 ± 0.271.14 ± 0.261.19 ± 0.291.16 ± 0.280.740
Total bilirubin (mmol/L)12.79 ± 3.3413.44 ± 3.8911.55 ± 4.0411.21 ± 3.890.002
AST (U/L)21.76 ± 9.0822.62 ± 9.1522.38 ± 8.7822.40 ± 9.600.930
ALT (U/L)21.16 ± 8.6622.78 ± 9.3523.16 ± 8.9222.61 ± 8.330.4251
Table 2 Multiple logistic regression analysis of the association between clinical characteristics and diabetic retinopathy/proliferative diabetic retinopathy risk
DR
PDR
Multivariate OR (95%CI)
P value
Multivariate OR (95%CI)
P value
Age (10 yr)0.03 (0.008 to 0.063)0.1340.939 (0.003 to 0.011)0.005
Diabetes duration(1 yr)0.032 (0.025 to 0.039)< 0.0010.007 (0.007 to 0.023)0.002
Hypertension-0.023 (-0.105 to 0.059)0.5770.015 (-0.129 to 0.022)< 0.001
BMI-0.008 (-0.019 to 0.001)0.090-0.053 (-0.023 to -0.001)0.166
Smoking-0.033 (-0.109 to 0.044)0.402-0.012 (-0.098 to 0.075)0.032
Drinking-0.023 (-0.096 to 0.050)0.532-0.012 (-0.143 to 0.021)0.791
FBG (mg/dL)0.002 (0.001 to 0.003)< 0.001-0.061 (0.001 to 0.004)0.143
HbA1C (%)0.017 (-0.002 to 0.036)0.0840.002 (-0.006 to 0.037)< 0.001
Total bilirubin (mmol/L)0.004 (-0.006 to 0.014)0.4280.015 (-0.016 to 0.006)0.158
Melatonin (pg/mL)-0.008 (-0.010 to -0.005)< 0.001-0.005 (-0.004 to 0.002)0.412
Table 3 Correlations between baseline information and laboratory data and plasma melatonin concentrations
Baseline information and laboratory data
Plasma melatonin concentrations
r
P value
Age-0.10180.078
Gender-0.14280.013
Diabetes duration-0.5623< 0.001
SBP-0.2224< 0.001
DBP-0.13260.022
MAP-0.2146< 0.001
Hypertension0.14290.013
BMI-0.090460.118
Smoking-0.05430.349
Drinking-0.061590.288
FBG (mg/dL)-0.464< 0.001
HbA1C (%)-0.481< 0.001
Triglycerides (mmol/L)0.042240.466
Total cholesterol (mmol/L)0.015440.790
LDL cholesterol (mmol/L)0.028130.628
HDL cholesterol (mmol/L-0.015870.784
Total bilirubin (mmol/L)0.4386< 0.001
AST (U/L)-0.065360.259
ALT (U/L)-0.068150.239